1010-00003 · Arbor Health Technologies Inc · Self-Assessment & Risk Analysis

pinnacle-laboratory-aks-stark-analysis.docx DOCUMENT Funds

29 / 35 ← → ✕

MEMORANDUM

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

TO: Patricia Yamamoto, General Counsel, Arbor Health Technologies Inc. Derek Huang, Chief Compliance Officer, Arbor Health Technologies Inc.

FROM: Miriam Calloway, Partner, Calderwood & Harkness LLP Christopher Aiken, Senior Associate, Calderwood & Harkness LLP Amy Whitfield, Associate, Calderwood & Harkness LLP

DATE: May 15, 2023

RE: Pinnacle Laboratory Services Inc. — Detailed Analysis Under the Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) and the Physician Self-Referral Law (42 U.S.C. § 1395nn)

C&H Matter No.: 1010-00003

This memorandum is a privileged and confidential attorney-client communication and attorney work product prepared by Calderwood & Harkness LLP at the direction of Arbor Health Technologies Inc. for the purpose of providing legal advice in connection with AHT's healthcare regulatory compliance self-assessment. This memorandum is not intended for distribution to any third party without the prior written consent of Calderwood & Harkness LLP and Arbor Health Technologies Inc. Disclosure to any third party may waive applicable privileges.

Right-click to update Table of Contents

I. EXECUTIVE SUMMARY

This memorandum presents a standalone legal analysis of three discrete compliance issues arising from the relationship between Arbor Health Technologies Inc. ("AHT") and Pinnacle Laboratory Services Inc. ("Pinnacle") under the Federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b (the "AKS"), and the Federal Physician Self-Referral Law, 42 U.S.C. § 1395nn (the "Stark Law"). This memorandum has been prepared at the direction of AHT's General Counsel, Patricia Yamamoto, and Chief Compliance Officer, Derek Huang, in connection with the broader healthcare regulatory compliance self-assessment engagement between AHT and Calderwood & Harkness LLP (engagement letter dated January 30, 2023; engagement window January 30, 2023 through July 12, 2023).

This memorandum supplements, and should be read in conjunction with, the comprehensive Stark Law Compliance Assessment Memorandum and the Anti-Kickback Statute Compliance Assessment Memorandum separately prepared by Calderwood & Harkness LLP as part of the broader self-assessment engagement. Those memoranda address the full universe of AHT's physician referral arrangements and financial relationships on a portfolio-wide basis. The present memorandum narrows its focus to the Pinnacle relationship specifically, which warrants dedicated attention given its complexity and risk profile.

The Pinnacle relationship was initially identified as a "high-risk" arrangement in the gap assessment report prepared by Grayson Whitaker & Associates LLP (Report No. GW-AHT-2022-Final, dated December 12, 2022), which was commissioned by AHT prior to the engagement of Calderwood & Harkness LLP. The Grayson Whitaker report flagged several features of the arrangement that warranted further legal analysis, including the absence of fair market value ("FMV") substantiation for certain items and services, the intermingling of referral and vendor relationships, and potential undisclosed conflicts of interest. Calderwood & Harkness LLP has independently investigated the factual circumstances and conducted the legal analysis that follows.

Three issues are analyzed in this memorandum:

1. No-Cost Electronic Laboratory Interface ("LabLink Interface"). Pinnacle provides a proprietary electronic laboratory ordering and results interface integrated into AHT's ArborConnect electronic health record ("EHR") platform at zero cost to AHT, under the preferred laboratory agreement dated June 15, 2020. The estimated fair market value of this interface is approximately $120,000 per year, based on comparable SaaS licensing arrangements for laboratory interface products, as assessed by AHT internal IT and validated by preliminary benchmarking conducted by Calderwood & Harkness LLP. The interface effectively channels AHT physician laboratory orders exclusively to Pinnacle.

2. Continuing Medical Education ("CME") Sponsorship. Pinnacle sponsored four CME events for AHT physicians in fiscal year 2022, with an aggregate sponsorship value of $86,000. The events covered clinical laboratory topics and were attended by AHT physicians who are sources of referrals to Pinnacle for clinical laboratory services.

3. Dr. Karen Ellsworth's Equity Interest. Dr. Karen Ellsworth, an independent physician and the spouse of Dr. Nathan Ellsworth (Chief Executive Officer of AHT), holds a 4.2% passive equity interest in Pinnacle Laboratory Services Inc. This equity interest was not disclosed in AHT's conflict-of-interest records prior to the Grayson Whitaker gap assessment.

Referral Volume. AHT clinics located in Rhode Island and southeastern Massachusetts generated approximately $1.65 million in outpatient clinical laboratory referrals to Pinnacle in fiscal year 2022. Given AHT's overall payer mix (approximately 61% Medicare/Medicaid, 39% commercial), the estimated Medicare and Medicaid share of this referral volume is approximately $1.0 million.

Overall Risk Assessment: HIGH. Based on the analysis set forth in this memorandum, Calderwood & Harkness LLP concludes that the Pinnacle arrangement presents material compliance risk under both the AKS and the Stark Law. Each of the three issues independently raises significant legal concerns, and the three issues taken together create a compounding effect that substantially elevates the overall risk profile. Remediation is strongly recommended.

Key Recommendations. Calderwood & Harkness LLP recommends the following remedial actions, each of which is described in greater detail in Section VIII of this memorandum:

(a) Restructure the LabLink Interface to a fair market value software license arrangement, supported by an independent FMV appraisal, with terms that satisfy applicable AKS safe harbors and Stark Law exceptions;

(b) Decouple CME sponsorship from the referral relationship by transitioning to AHT-funded or independently accredited CME programming, with any residual non-monetary benefits compliant with applicable thresholds;

(c) Implement formal conflict-of-interest disclosure and management protocols for Dr. Karen Ellsworth's 4.2% equity interest in Pinnacle, including CEO recusal from Pinnacle-related decisions, board-level disclosure, and consideration of divestiture; and

(d) Evaluate whether voluntary self-disclosure is warranted under the CMS Self-Referral Disclosure Protocol ("SRDP") and the OIG Self-Disclosure Protocol ("SDP"), as discussed in the companion CMS SRDP Evaluation Memorandum and OIG SDP Evaluation Memorandum.

II. FACTUAL BACKGROUND

The following factual background is based on Calderwood & Harkness LLP's review of documents provided by AHT, interviews with AHT management and compliance personnel, the Grayson Whitaker gap assessment report, publicly available information, and other materials gathered during the course of this engagement. All factual statements herein are based on information available as of the date of this memorandum.

A. Arbor Health Technologies Inc. — Overview

Arbor Health Technologies Inc. ("AHT") is a Delaware corporation headquartered at 200 Concord Avenue, Suite 400, Cambridge, Massachusetts 02138. AHT was incorporated in Delaware in 2017 and is registered to do business in Massachusetts, Connecticut, Rhode Island, and New Hampshire.

AHT operates 23 outpatient medical clinics branded as "Arbor Health Clinics" across four states in the northeastern United States. The clinic distribution is as follows: fourteen (14) clinics in Massachusetts, four (4) clinics in Connecticut, three (3) clinics in Rhode Island, and two (2) clinics in New Hampshire. The clinics provide a range of healthcare services, including primary care, specialty care (cardiology, orthopedics, and gastroenterology), and ancillary services such as in-office laboratory testing, diagnostic imaging, and physical therapy.

In addition to its clinical operations, AHT has developed and markets a proprietary electronic health record and practice management software-as-a-service ("SaaS") platform known as "ArborConnect." ArborConnect is used internally by all 23 AHT clinics and is also licensed to 42 external physician practices, generating approximately $8.9 million in annual subscription revenue. The ArborConnect platform is central to the LabLink Interface issue discussed in this memorandum, as the Pinnacle electronic laboratory interface is integrated directly into the ArborConnect system.

For fiscal year 2022 ("FY2022"), AHT reported net revenue of $214.3 million. Of this total, Medicare and Medicaid reimbursements accounted for approximately 61%, or $130.7 million. Commercial payer revenue accounted for the remaining 39%, or approximately $83.6 million. AHT's payer mix is relevant to the magnitude of potential Stark Law exposure, as the Stark Law's prohibition on referrals and billing applies specifically to items and services payable by the Medicare program.

AHT employs 147 physicians on a W-2 basis across its 23 clinics. In addition, AHT maintains 38 independent contractor or medical director arrangements with non-employed physicians. These physicians, whether employed or under contract, are the individuals who order and refer clinical laboratory services that are at issue in the Pinnacle relationship.

AHT is a portfolio company of Ridgeline Capital Partners Fund IV, L.P. ("Ridgeline"), a private equity fund. Ridgeline acquired a 72% equity stake in AHT in January 2021 for approximately $185 million. Ridgeline's board designees are Claudia Sorrento and Marcus Whitmore, each of whom serves on AHT's Board of Directors. Ridgeline is currently anticipated to pursue an exit or sale of its AHT interest in late 2024, a fact that has significant implications for the urgency of compliance remediation, as discussed further in Section VII.C of this memorandum.

AHT's current senior leadership includes Dr. Nathan Ellsworth, Chief Executive Officer; Patricia Yamamoto, General Counsel; and Derek Huang, Chief Compliance Officer. AHT's employer identification number ("EIN") is 84-3291057. Its organizational National Provider Identifier ("NPI") is 1497253810, and its lead Provider Transaction Access Number ("PTAN") is 27MA4891.

As of the date of this memorandum, AHT has no prior federal or state healthcare enforcement actions, has not entered into a Corporate Integrity Agreement with the OIG, and has no pending OIG Advisory Opinion requests.

B. Pinnacle Laboratory Services Inc. — Overview

Pinnacle Laboratory Services Inc. ("Pinnacle") is a Rhode Island corporation with its principal place of business at 1200 Warwick Avenue, Suite 110, Warwick, Rhode Island 02886. Pinnacle's employer identification number is 05-6138290.

Pinnacle provides clinical laboratory testing services, including routine chemistry panels, hematology, complete blood counts, urinalysis, microbiology and culture testing, anatomic and clinical pathology, and specialized molecular diagnostics. Pinnacle holds appropriate CLIA certifications and state laboratory licenses for the jurisdictions in which it operates.

Pinnacle services AHT's three Rhode Island clinics and a relevant subset of AHT's fourteen Massachusetts clinics located in southeastern Massachusetts. The specific Massachusetts clinics serviced by Pinnacle include those in Fall River, New Bedford, Taunton, and Brockton. Pinnacle is the designated "preferred" outpatient clinical laboratory for these AHT clinics under the terms of the Preferred Laboratory Agreement discussed below.

Based on information gathered during this engagement, Pinnacle is a privately held company. It is not publicly traded, and its equity is not available through a registered stock exchange or over-the-counter market. This fact is relevant to the applicability of certain AKS safe harbors and Stark Law exceptions, as discussed in Sections V and VI of this memorandum.

C. The Preferred Laboratory Agreement

AHT and Pinnacle entered into a Preferred Laboratory Agreement (the "PLA") on June 15, 2020. Under the PLA, Pinnacle is designated as the "preferred" outpatient clinical laboratory for AHT's Rhode Island and southeastern Massachusetts clinics. The PLA contemplates that AHT physicians at the designated clinics will direct, or at a minimum be encouraged to direct, outpatient laboratory work to Pinnacle as the preferred provider.

In FY2022, AHT clinics subject to the PLA generated approximately $1.65 million in outpatient laboratory referrals to Pinnacle. This volume represents a material revenue stream for Pinnacle and a significant referral relationship for purposes of AKS and Stark Law analysis.

The PLA contains several provisions that are relevant to this analysis. First, the PLA provides for the designation of Pinnacle as the provider of an electronic laboratory ordering and results interface (the "LabLink Interface") integrated into AHT's ArborConnect EHR platform at no cost to AHT. Second, the PLA contemplates Pinnacle's sponsorship of continuing medical education events for AHT physicians. These two provisions form the basis of Issues 1 and 2 addressed in this memorandum.

The PLA does not contain a specific provision regarding Dr. Karen Ellsworth's equity interest in Pinnacle, nor does it include any conflict-of-interest disclosure requirements related to the financial interests of AHT officers or their immediate family members.

The PLA was executed for an initial term of three years and contains an automatic renewal provision for successive one-year terms unless either party provides written notice of non-renewal at least 90 days prior to the end of the then-current term. As of the date of this memorandum, the PLA remains in effect and has not been modified or amended since its original execution.

D. The Electronic Laboratory Interface (LabLink Interface)

Under the PLA, Pinnacle provides a proprietary electronic laboratory ordering and results interface, branded as the "LabLink Interface," which is integrated into AHT's ArborConnect EHR platform. The LabLink Interface enables AHT physicians to place clinical laboratory orders electronically from within the ArborConnect system, receive laboratory results directly in the patient's electronic health record, and generate automated billing and coding data associated with the ordered tests.

The LabLink Interface was implemented approximately in mid-2020, shortly after the execution of the PLA. It has been in continuous operation since that time. The cost to AHT for the LabLink Interface is zero dollars — the interface is provided by Pinnacle at no charge as part of the preferred laboratory arrangement.

The estimated fair market value of the LabLink Interface is approximately $120,000 per year. This estimate is based on comparable SaaS licensing arrangements for laboratory interface products, as initially assessed by AHT's internal IT department and validated by preliminary benchmarking conducted by Calderwood & Harkness LLP in consultation with industry databases and publicly available pricing information for laboratory information system interface products. A formal, independent FMV appraisal has not been conducted; Calderwood & Harkness LLP recommends engagement of Northbridge Valuation Advisors LLC for this purpose, as discussed in Section VIII.A.

A critical feature of the LabLink Interface is its exclusive routing functionality. Laboratory orders placed through ArborConnect are routed exclusively to Pinnacle. The interface does not provide AHT physicians with the option to direct laboratory orders to an alternative laboratory provider through the same workflow. This "lock-in" effect means that the LabLink Interface is not merely a convenience tool but a structural mechanism that channels referral volume to Pinnacle. To order from a different laboratory, an AHT physician would need to step outside the ArborConnect workflow and use an alternative ordering process, creating friction that discourages deviation from the Pinnacle referral pathway.

The combination of zero cost and exclusive routing makes the LabLink Interface a significant element of the Pinnacle relationship for purposes of AKS and Stark Law analysis.

E. CME Sponsorship

Pinnacle has sponsored continuing medical education events for AHT physicians under the general framework of the PLA and the broader preferred laboratory relationship. In FY2022, Pinnacle sponsored four (4) CME events for AHT physicians, with an aggregate sponsorship value of $86,000.

The sponsorship covered speaker fees, venue rental, catering and meals, and CME credit administration costs. The events were held at a combination of AHT clinic locations and external venues (hotels and conference centers). The content of the CME events focused on clinical laboratory topics, including advances in molecular diagnostics, appropriate laboratory utilization guidelines, quality improvement in laboratory testing, and emerging biomarkers in cardiology and oncology screening.

The CME events were open to AHT physicians who practice at the clinics subject to the PLA and who are sources of referrals to Pinnacle. Attendance records provided by AHT indicate that each event was attended by approximately 25 to 35 AHT physicians. The events were not open to the general physician community; they were organized specifically for AHT physicians in connection with the Pinnacle preferred laboratory relationship.

There is no evidence that the CME events were independently accredited by an ACCME-accredited CME provider. The events appear to have been organized jointly by Pinnacle and AHT's medical education department, with Pinnacle having input into speaker selection and topic emphasis. This organizational structure raises concerns about the independence of the educational content and the extent to which the CME events served a marketing or relationship-building function in addition to (or instead of) a genuine educational purpose.

F. Dr. Karen Ellsworth's Equity Interest in Pinnacle

Dr. Karen Ellsworth holds a 4.2% passive equity interest in Pinnacle Laboratory Services Inc. Dr. Karen Ellsworth is a licensed physician practicing independently in Rhode Island. She is not employed by AHT, does not hold a medical directorship or independent contractor arrangement with AHT, and does not practice at any AHT clinic.

Dr. Karen Ellsworth is the spouse of Dr. Nathan Ellsworth, who serves as Chief Executive Officer of AHT. Dr. Nathan Ellsworth is a licensed physician who assumed the CEO role at AHT in connection with the Ridgeline Capital acquisition in January 2021. As CEO, Dr. Nathan Ellsworth has ultimate management authority over AHT's clinical operations, including physician employment and supervision, vendor relationships, preferred provider designations, and referral policies. Dr. Nathan Ellsworth's authority encompasses the decision to enter into, maintain, and renew the PLA with Pinnacle.

There is no evidence in the record that Dr. Karen Ellsworth directly participates in AHT's decision-making regarding the Pinnacle relationship. She has no formal role at AHT and has not communicated with AHT personnel regarding the PLA or any aspect of the Pinnacle arrangement, based on the information available to Calderwood & Harkness LLP. However, the spousal relationship between Dr. Karen Ellsworth and Dr. Nathan Ellsworth creates a financial interest that runs through AHT's CEO. As Dr. Karen Ellsworth's equity interest in Pinnacle generates financial returns (dividends, distributions, or appreciation in equity value), the economic benefit inures to the marital household of the individual who controls AHT's referral policies and vendor relationships.

Critically, the equity interest was not disclosed in AHT's conflict-of-interest records prior to the Grayson Whitaker gap assessment in late 2022. AHT's conflict-of-interest policy requires annual disclosure by officers and directors of financial interests in entities with which AHT does business, but the policy does not explicitly require disclosure of immediate family members' financial interests. The Grayson Whitaker gap assessment identified this deficiency and recommended expansion of the disclosure requirements. Calderwood & Harkness LLP concurs with this recommendation.

III. APPLICABLE LEGAL FRAMEWORK

A. Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b))

The Federal Anti-Kickback Statute, codified at 42 U.S.C. § 1320a-7b(b), prohibits any person from knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in exchange for, or to induce, the referral of an individual for the furnishing or arranging for the furnishing of any item or service payable under a federal healthcare program, or in exchange for, or to induce, the purchasing, leasing, ordering, or arranging for or recommending purchasing, leasing, or ordering any good, facility, service, or item payable under a federal healthcare program. 42 U.S.C. § 1320a-7b(b)(1)-(2).

Clinical laboratory services are items and services covered under the Medicare and Medicaid programs and thus fall within the scope of the AKS. The referral of laboratory testing from AHT physicians to Pinnacle, to the extent such testing is payable by Medicare, Medicaid, or any other federal healthcare program, implicates the statute's prohibitions.

The AKS is interpreted broadly. The statute's use of the terms "directly or indirectly" and "in cash or in kind" Signals that the prohibition extends beyond simple cash payments and encompasses any transfer of value that may serve as an inducement to refer. The United States Court of Appeals for the Third Circuit, in United States v. Greber, 760 F.2d 68 (3d Cir. 1985), held that a violation of the AKS exists if even one purpose of a payment is to induce future referrals, regardless of whether the payment also compensates for legitimate services. This "one-purpose test" has been widely adopted by other circuits and represents the prevailing standard for AKS enforcement.

Violations of the AKS carry significant penalties. A criminal conviction under the AKS is a felony offense, punishable by up to five years of imprisonment and a fine of up to $100,000 per violation. 42 U.S.C. § 1320a-7b(b). In addition to criminal penalties, the Civil Monetary Penalties Law ("CMPL"), 42 U.S.C. § 1320a-7a, authorizes civil monetary penalties of up to $100,000 per violation, plus treble the amount of remuneration involved. Persons convicted of AKS violations are also subject to mandatory exclusion from federal healthcare programs under 42 U.S.C. § 1320a-7(a).

Furthermore, AKS violations serve as a predicate for liability under the False Claims Act ("FCA"), 31 U.S.C. § 3729 et seq. Section 1320a-7b(g) provides that a claim for items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. FCA liability exposes the violating party to treble damages and per-claim penalties (currently $13,946 to $27,894 per claim, as adjusted for inflation), as well as potential qui tam actions brought by whistleblower relators.

B. AKS Safe Harbors (42 C.F.R. § 1001.952) — Potentially Applicable

Congress directed the OIG to promulgate regulations specifying payment practices that shall not be treated as criminal offenses under the AKS. These "safe harbors," codified at 42 C.F.R. § 1001.952, define specific arrangements that, if all conditions are met, will not be subject to prosecution under the AKS. Compliance with a safe harbor is voluntary but provides definitive protection when all elements are satisfied. Failure to meet every element of a safe harbor does not necessarily mean that an arrangement violates the AKS; it means only that the arrangement does not have the benefit of safe harbor protection and must be evaluated on a case-by-case basis under the totality of the circumstances.

The following safe harbors are potentially relevant to the three issues analyzed in this memorandum:

Investment Interests Safe Harbor (42 C.F.R. § 1001.952(a)). This safe harbor protects certain returns on investment interests in entities from which the investor receives referrals or to which the investor makes referrals. For entities whose equity securities are not traded on a public exchange (as is the case with Pinnacle), the safe harbor imposes stricter requirements, commonly referred to as the "60/40 test." Specifically, for non-publicly traded entities, the safe harbor requires, among other conditions: (i) no more than 40% of the value of the investment interests may be held in the aggregate by investors who are in a position to make or influence referrals to, furnish items or services to, or otherwise generate business for the entity; (ii) no more than 40% of the entity's gross revenue related to the furnishing of healthcare items and services in the previous fiscal year or twelve-month period may come from referrals, items, or services furnished to investors; (iii) the terms on which an investment interest is offered to a passive investor who is in a position to make or influence referrals must be no different from the terms offered to other passive investors; (iv) the terms on which the investment interest is offered must not require the investor to make referrals to the entity; (v) the entity must not loan funds to or guarantee a loan for an investor who is in a position to make referrals if the loan or guarantee is used to obtain the investment interest; and (vi) the return on the investment must be directly proportional to the amount of the capital investment. 42 C.F.R. § 1001.952(a)(2).

Personal Services and Management Contracts Safe Harbor (42 C.F.R. § 1001.952(d)). This safe harbor protects payments made by a principal to an agent for services performed under a personal services or management contract, provided that several conditions are satisfied: (i) the agreement is in writing and signed by the parties; (ii) the agreement covers all services to be provided by the agent; (iii) if the agreement is for part-time or periodic services, the agreement specifies the schedule, length, and exact charge for such intervals; (iv) the term of the agreement is for not less than one year; (v) the aggregate compensation paid over the term of the agreement is set in advance, is consistent with fair market value in arm's-length transactions, and is not determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties; and (vi) the services performed do not involve the counseling or promotion of a business arrangement or other activity that violates any state or federal law. 42 C.F.R. § 1001.952(d).

Electronic Health Records Items and Services Safe Harbor (42 C.F.R. § 1001.952(y)). This safe harbor, originally promulgated in 2006 and subject to periodic sunset and reinstatement, protects certain donations of electronic health records software, information technology, and training services. As amended and extended by the 2020 Final Rule (85 Fed. Reg. 77684), the safe harbor requires, among other conditions: (i) the items and services are provided to an individual or entity engaged in the delivery of healthcare; (ii) the donor does not take any action to limit or restrict the use, compatibility, or interoperability of the donated items or services with other electronic prescribing or electronic health records systems; (iii) neither the eligibility of a recipient for the items or services, nor the amount or nature of the items or services, is determined in a manner that directly takes into account the volume or value of referrals or other business generated between the parties; (iv) the arrangement is set forth in a written agreement signed by the parties; and (v) the donor does not have actual knowledge of, and does not act in reckless disregard or deliberate ignorance of, the fact that the recipient possesses or has obtained items or services equivalent to those provided. 42 C.F.R. § 1001.952(y).

C. Physician Self-Referral Law (Stark Law) (42 U.S.C. § 1395nn)

The Physician Self-Referral Law, commonly known as the "Stark Law," is codified at 42 U.S.C. § 1395nn and its implementing regulations at 42 C.F.R. Part 411, Subparts J and K. The Stark Law operates as a strict liability prohibition: it does not require proof of intent, knowledge, or willfulness. If the elements of the prohibition are met and no exception applies, a violation exists regardless of the parties' state of mind.

The Stark Law provides that if a physician (or an immediate family member of such physician) has a "financial relationship" with an entity, the physician may not make a referral to the entity for the furnishing of "designated health services" ("DHS") payable by the Medicare program, unless an exception applies. 42 U.S.C. § 1395nn(a)(1). Furthermore, the entity may not present or cause to be presented a claim to Medicare (or bill any other individual, entity, or third-party payer) for DHS furnished pursuant to a prohibited referral. 42 U.S.C. § 1395nn(a)(1)(B).

Designated Health Services. The Stark Law identifies ten categories of DHS, including clinical laboratory services. 42 U.S.C. § 1395nn(h)(6). Pinnacle provides clinical laboratory testing services that fall squarely within this category.

Financial Relationship. The term "financial relationship" encompasses two types of arrangements: (1) an ownership or investment interest in the entity, including equity interests, debt instruments, or other means of investment; and (2) a compensation arrangement between the physician (or an immediate family member) and the entity. 42 U.S.C. § 1395nn(a)(2); 42 C.F.R. § 411.354. Both direct and indirect financial relationships are covered.

Immediate Family Member. The Stark Law extends the prohibition to referrals by a physician whose "immediate family member" has a financial relationship with the DHS entity. The term "immediate family member" is defined at 42 C.F.R. § 411.351 to include, among others, a spouse.

Referral. The term "referral" is defined broadly to include "the request by a physician for, or ordering of, or the certifying or recertifying of the need for" any designated health service. 42 U.S.C. § 1395nn(h)(5).

Penalties. Violations of the Stark Law result in: (i) denial of payment for the DHS furnished pursuant to the prohibited referral; (ii) an obligation to refund any amounts collected for such DHS; (iii) civil monetary penalties of up to $15,000 per service furnished pursuant to a prohibited referral; (iv) for circumvention schemes, a civil monetary penalty assessment of up to $100,000; and (v) potential exclusion from federal healthcare programs. 42 U.S.C. § 1395nn(g); 42 C.F.R. § 411.353.

D. Stark Law Exceptions — Potentially Applicable

The Stark Law provides numerous exceptions, codified at 42 U.S.C. § 1395nn(b)-(e) and 42 C.F.R. §§ 411.355-411.357. If an exception applies, the prohibition on referrals and billing does not attach. The following exceptions are potentially relevant to the issues analyzed in this memorandum:

Ownership/Investment Interest Exception for Publicly Traded Securities and Mutual Funds (42 C.F.R. § 411.356(a)). This exception applies to ownership of investment securities that may be purchased on terms generally available to the public and that are listed on a registered national securities exchange or traded under an automated interdealer quotation system. Because Pinnacle does not appear to be a publicly traded entity, this exception is not applicable to Dr. Karen Ellsworth's equity interest.

Ownership/Investment Interest in Rural Providers (42 C.F.R. § 411.356(c)). This exception permits ownership or investment interests in entities that furnish DHS in a "rural area," as defined in the regulations. Pinnacle is located in Warwick, Rhode Island, which is a suburb of Providence and is not classified as a rural area under applicable definitions (including the Census Bureau's designation of the Providence-Warwick-Pawtucket metropolitan statistical area). This exception is not applicable.

Indirect Compensation Arrangement Exception (42 C.F.R. § 411.357(p)). This exception applies to indirect compensation arrangements and requires that: (i) the compensation received by the referring physician (or immediate family member) under the arrangement does not vary with, and is not otherwise determined by taking into account, the volume or value of referrals or other business generated by the referring physician; (ii) the compensation arrangement is set out in writing, is signed by the parties, and specifies the services covered by the arrangement; and (iii) the compensation provided under the arrangement is consistent with FMV for services or items actually provided and is not determined in a manner that takes into account the volume or value of referrals or other business generated between the parties.

Non-Monetary Compensation Exception (42 C.F.R. § 411.357(k)). This exception permits an entity that furnishes DHS to provide non-monetary compensation to a referring physician if the aggregate value of the non-monetary compensation does not exceed the annual threshold established by CMS. For calendar year 2023, this threshold is $459 per physician. The exception does not apply if the physician has specifically requested the compensation.

Fair Market Value Exception (42 C.F.R. § 411.357(l)). This exception applies to compensation arrangements for the provision of items or services (other than the rental of office space or equipment) that meet the following requirements: (i) the arrangement is in writing, signed by the parties, and specifies the items or services covered; (ii) the arrangement covers only identifiable items or services; (iii) the compensation is set in advance, does not exceed FMV, and is not determined in a manner that takes into account the volume or value of referrals; and (iv) the arrangement is commercially reasonable.

Value-Based Enterprise Exceptions (42 C.F.R. § 411.357(aa)). The CMS Final Rule effective January 19, 2021 (85 Fed. Reg. 77492) established new Stark Law exceptions for value-based arrangements. These exceptions permit certain remuneration exchanged between participants in a "value-based enterprise" that is reasonably designed to achieve at least one value-based purpose. The applicability of these exceptions depends on whether AHT and Pinnacle could constitute a "value-based enterprise" and whether any arrangement between them qualifies as a "value-based arrangement" as defined in the regulations. Based on preliminary analysis, the AHT-Pinnacle relationship does not appear to be structured as a value-based enterprise, and no value-based arrangement appears to exist between the parties. However, a more detailed analysis of this exception is reserved for the comprehensive Stark Law Compliance Assessment Memorandum.

E. State Law Overlay

In addition to the federal AKS and Stark Law, several state laws may be implicated by the Pinnacle arrangement. Of particular relevance is the Massachusetts Anti-Kickback Law, codified at M.G.L. c. 175H, § 3, which prohibits the payment or receipt of remuneration for the referral of patients in connection with healthcare services. Unlike the federal AKS, which applies only to items and services payable by federal healthcare programs, the Massachusetts Anti-Kickback Law extends to referrals involving commercial payer patients. This broader scope means that the 39% of AHT's revenue attributable to commercial payers — approximately $83.6 million in FY2022 — may be subject to state-level kickback prohibitions in Massachusetts.

AHT's southeastern Massachusetts clinics that refer laboratory work to Pinnacle involve both federal program patients and commercial payer patients. Accordingly, even if the federal AKS analysis were limited to the Medicare/Medicaid share of referral volume, the Massachusetts Anti-Kickback Law may capture the full scope of referral-related remuneration.

A detailed analysis of Massachusetts state law applicability is provided in the companion Massachusetts Anti-Kickback Law (M.G.L. c. 175H, § 3) Applicability Memorandum. Rhode Island healthcare anti-fraud statutes (R.I. Gen. Laws § 27-60-1 et seq.) and their potential applicability to the Pinnacle arrangement should also be evaluated and are addressed in the comprehensive AKS Compliance Assessment Memorandum.

IV. ANALYSIS — ISSUE 1: NO-COST ELECTRONIC LABORATORY INTERFACE

A. Characterization of the Arrangement

The threshold question for both AKS and Stark Law analysis is whether the provision of the LabLink Interface at zero cost constitutes "remuneration." Under both statutes, remuneration is defined broadly to include transfers of anything of value, directly or indirectly, overtly or covertly, in cash or in kind. The LabLink Interface is a functional, commercially available software product with an estimated fair market value of approximately $120,000 per year. Its provision at no cost to AHT constitutes a transfer of value — i.e., remuneration — from Pinnacle to AHT.

The remuneration flows from Pinnacle (an entity that receives referrals from AHT physicians for clinical laboratory services that are DHS under the Stark Law and items payable by federal healthcare programs under the AKS) to AHT (the entity whose physicians make the referrals that generate Pinnacle's revenue). This directionality of the remuneration — from the recipient of referrals to the source of referrals — is precisely the type of arrangement that both statutes are designed to address.

The LabLink Interface is directly tied to the PLA and facilitates referrals by making it operationally easier, faster, and more seamless for AHT physicians to order laboratory services from Pinnacle. The interface eliminates the need for AHT physicians to complete paper requisitions, call Pinnacle directly, or use an alternative ordering system. The integration of the LabLink Interface into ArborConnect means that ordering from Pinnacle is the default workflow; ordering from any other laboratory requires additional effort and deviation from the standard process.

Most significantly, the LabLink Interface creates a structural "lock-in" effect. Because orders placed through ArborConnect route exclusively to Pinnacle, the interface channels referral volume to Pinnacle with no competing option within the same workflow. This lock-in effect strengthens the inference that the interface serves as an inducement to refer to Pinnacle. The interface is not merely a neutral technology tool; it is a referral-generating mechanism embedded in the physician's daily clinical workflow, provided at no cost by the entity that benefits from the referrals it generates.

B. Anti-Kickback Statute Analysis

1. Prima Facie Case

The elements of a potential AKS violation are present. Pinnacle provides an item of value — the LabLink Interface, with an estimated FMV of $120,000 per year — to AHT, an entity whose physicians refer clinical laboratory services to Pinnacle. In FY2022, AHT physicians referred approximately $1.65 million in outpatient laboratory services to Pinnacle. Under the "one-purpose test" articulated in United States v. Greber, a reasonable inference exists that at least one purpose of the no-cost interface is to induce or reward referrals from AHT physicians to Pinnacle for laboratory services payable by federal healthcare programs.

The inference of inducement is supported by several factual indicators. First, the LabLink Interface was provided contemporaneously with the PLA, which designated Pinnacle as the preferred laboratory for AHT's relevant clinics. The interface and the preferred laboratory designation are components of a single integrated arrangement. Second, the interface creates a lock-in effect that channels referrals exclusively to Pinnacle. Third, the value of the interface ($120,000 per year) is substantial — it is not a de minimis courtesy or incidental convenience. Fourth, there is no independent commercial rationale for Pinnacle to provide a $120,000-per-year product at no cost other than the generation and retention of referral volume.

2. Safe Harbor Analysis — Personal Services (42 C.F.R. § 1001.952(d))

The personal services and management contracts safe harbor does not apply to the LabLink Interface arrangement. The provision of the interface is not structured as a personal services contract. The PLA does not contain a separate, written agreement specifying the LabLink Interface as a service with aggregate compensation set in advance at fair market value. Rather, the interface is bundled into the broader preferred laboratory arrangement as a zero-cost component. There is no specification of the services to be performed, no identification of the schedule of services, and no aggregate compensation that is set in advance and consistent with FMV. Accordingly, the personal services safe harbor does not protect this arrangement.

3. Safe Harbor Analysis — Electronic Health Records (42 C.F.R. § 1001.952(y))

The EHR items and services safe harbor requires careful analysis. This safe harbor was designed to encourage the adoption and use of electronic health records technology by permitting certain donations of EHR software and related services. However, the safe harbor was not designed to protect laboratory-specific ordering interfaces that function as referral-channeling mechanisms tied to a preferred provider relationship.

Calderwood & Harkness LLP has analyzed each element of the EHR safe harbor against the LabLink Interface arrangement:

(a) Written Agreement. The safe harbor requires that the arrangement be set forth in a written agreement signed by the parties that covers all of the items and services to be provided. The PLA references the LabLink Interface but does not contain the level of specificity required by the safe harbor — it does not separately identify the software components, functionality, support services, or other items and services constituting the "donation," nor does it include the specific representations and certifications contemplated by the safe harbor regulations.

(b) Interoperability. The safe harbor requires that the donor not take any action to limit or restrict the use, compatibility, or interoperability of the donated items or services with other electronic prescribing or EHR systems. The LabLink Interface, by design, routes laboratory orders exclusively to Pinnacle. It does not interoperate with other laboratory service providers. AHT physicians cannot use the LabLink Interface to order from a competing laboratory. This exclusive routing functionality represents a significant restriction on interoperability and is inconsistent with the safe harbor's requirement that the donated technology not be artificially limited to channel business to the donor.

(c) Volume or Value of Referrals. The safe harbor requires that neither the eligibility of the recipient for the items or services nor the amount or nature of the items or services be determined in a manner that directly takes into account the volume or value of referrals or other business generated between the parties. The LabLink Interface is provided exclusively in connection with the PLA, which designates Pinnacle as the preferred laboratory. The interface is, by its nature, linked to the referral relationship — it exists to facilitate referrals to Pinnacle. While the interface is provided at a flat zero-cost rate (not nominally tied to referral volume), its provision is inseparable from the preferred laboratory designation and the referral volume that designation generates. This coupling raises serious concerns about whether the arrangement satisfies the safe harbor's prohibition on volume-or-value-based determinations.

(d) Purpose of the Safe Harbor. More broadly, the EHR safe harbor was intended to promote the adoption of interoperable EHR technology, not to protect proprietary laboratory ordering interfaces that function as competitive lock-in mechanisms. The LabLink Interface is a narrow, single-purpose tool designed to route orders to Pinnacle. It is not an EHR system or a component of an EHR system in the traditional sense; it is a laboratory-specific ordering module that serves Pinnacle's commercial interests. Extending the EHR safe harbor to protect this type of arrangement would be inconsistent with the safe harbor's underlying policy rationale.

Conclusion: The EHR safe harbor likely does not protect the LabLink Interface arrangement in its current form. The exclusive routing functionality, the absence of interoperability with competing laboratories, the coupling of the interface with the preferred laboratory referral designation, and the lack of a sufficiently specific written agreement all present significant obstacles to safe harbor compliance.

4. Other Safe Harbors

No other AKS safe harbor appears applicable to the no-cost provision of the LabLink Interface. The arrangement does not qualify as a discount, a warranty, or a bona fide employment relationship. The waiver-of-coinsurance safe harbor is not relevant. The group purchasing organization safe harbor does not apply. The arrangement does not fall within the scope of the managed care safe harbor or the referral services safe harbor.

5. Overall AKS Conclusion on Issue 1

The no-cost provision of the LabLink Interface presents a significant AKS violation risk. The arrangement involves the transfer of substantial value ($120,000 per year) from a laboratory that receives referrals to the entity whose physicians make those referrals, in connection with a preferred laboratory designation that generates $1.65 million in annual referral volume. No safe harbor protects the arrangement in its current form. Under the one-purpose test, the likelihood that a government enforcement authority would conclude that at least one purpose of the no-cost interface is to induce referrals is substantial.

C. Stark Law Analysis

1. Compensation Arrangement Analysis

Under the Stark Law, the no-cost provision of the LabLink Interface constitutes remuneration from Pinnacle to AHT, creating a compensation arrangement between a DHS entity (Pinnacle, which provides clinical laboratory services) and an entity whose physicians make referrals for DHS. The existence of this compensation arrangement triggers the Stark Law prohibition unless an applicable exception is met.

2. Non-Monetary Compensation Exception (42 C.F.R. § 411.357(k))

The non-monetary compensation exception permits an entity that furnishes DHS to provide non-monetary compensation to a referring physician, provided that the aggregate value of the non-monetary compensation does not exceed the annual threshold established by CMS. For calendar year 2023, the threshold is $459 per physician per calendar year.

The LabLink Interface has an estimated fair market value of $120,000 per year. Even if this value is allocated across all AHT physicians who use the interface for laboratory ordering, the per-physician value substantially exceeds the $459 threshold. For example:

• If 50 AHT physicians regularly use the LabLink Interface, the per-physician allocation is $120,000 ÷ 50 = $2,400 per physician per year — more than five times the annual limit.

• If 100 AHT physicians use the interface (an unlikely scenario given that only a subset of AHT's 147 employed physicians practice at the clinics subject to the PLA), the per-physician allocation is $120,000 ÷ 100 = $1,200 per physician per year — still more than 2.6 times the annual limit.

• Even under the most generous allocation assumptions, the per-physician value of the LabLink Interface far exceeds $459.

Accordingly, the non-monetary compensation exception does not protect this arrangement.

3. Fair Market Value Exception (42 C.F.R. § 411.357(l))

The fair market value exception requires that compensation under the arrangement be consistent with fair market value for identifiable items or services actually provided. The LabLink Interface is provided at zero cost — not at FMV. Because the compensation (zero) is not consistent with the FMV of the services provided (approximately $120,000 per year), the fair market value exception does not apply. This exception could only be satisfied if AHT paid Pinnacle FMV for the interface, which is precisely the remedial action recommended in Section VIII.A.

4. Indirect Compensation Arrangement Exception (42 C.F.R. § 411.357(p))

If the LabLink Interface is characterized as compensation flowing from Pinnacle to AHT (rather than directly to individual physicians), the referring physicians' relationship with Pinnacle may be analyzed as an indirect compensation arrangement under 42 C.F.R. § 411.354(c). Under this analysis, there is an unbroken chain of financial relationships between Pinnacle (which provides remuneration in the form of the LabLink Interface to AHT) and the AHT physicians (who are employed by or under contract with AHT and who make referrals to Pinnacle for DHS).

The indirect compensation arrangement exception at 42 C.F.R. § 411.357(p) requires, among other things, that the compensation received by the physician (or immediate family member) under the arrangement does not vary with, and is not otherwise determined by taking into account, the volume or value of referrals or other business generated by the referring physician for the entity furnishing DHS.

This requirement is difficult to satisfy in the context of the LabLink Interface. Although the interface itself is provided at a flat rate (zero), it is provided in connection with the PLA, which designates Pinnacle as the preferred laboratory. The preferred laboratory designation is inherently tied to referral volume — it exists to generate referrals to Pinnacle. The LabLink Interface, as a component of the preferred laboratory arrangement, is linked to the $1.65 million in annual referral volume that the PLA generates. Whether the "compensation" (the no-cost interface) technically "varies with" the volume or value of referrals is debatable, but the functional nexus between the interface and the referral volume creates a substantial argument that the exception's requirements are not met.

Moreover, the exception requires that the compensation be consistent with FMV and not take into account the volume or value of referrals. As discussed above, the zero-cost provision of a $120,000-per-year product is not consistent with FMV.

5. Overall Stark Law Conclusion on Issue 1

The no-cost provision of the LabLink Interface likely constitutes a non-excepted compensation arrangement that renders referrals from AHT physicians to Pinnacle for DHS non-compliant under the Stark Law. No exception available under current regulations appears to protect the arrangement in its present form. If this analysis is correct, every referral from an AHT physician to Pinnacle for clinical laboratory services payable by Medicare that has occurred during the period the LabLink Interface has been in place (approximately June 2020 to the present) is a prohibited referral, and every Medicare claim submitted by Pinnacle for such services is a prohibited claim.

D. Overpayment and Refund Exposure

If the Stark Law is violated, all claims for DHS (clinical laboratory services) referred by AHT physicians to Pinnacle and billed to Medicare are subject to the statutory prohibition on billing and the refund obligation. Under 42 U.S.C. § 1395nn(g)(2), any person who collects any amounts that were billed in violation of the Stark Law is obligated to refund such amounts. Furthermore, under 42 U.S.C. § 1320a-7k(d), an overpayment must be reported and returned to the applicable payer within 60 days of the date on which the overpayment was identified, or the date any corresponding cost report is due, whichever is later. Failure to timely return an identified overpayment may give rise to FCA liability.

The potential overpayment exposure is calculated as follows:

• FY2022 referral volume to Pinnacle: Approximately $1.65 million total.

• Medicare/Medicaid share: Approximately 61% (consistent with AHT's overall payer mix) = approximately $1.0 million in Medicare/Medicaid-payable referrals.

• Duration of the arrangement: The LabLink Interface has been in place since approximately June 2020, encompassing FY2020 (partial year, approximately six months), FY2021 (full year), and FY2022 (full year), with the arrangement continuing into FY2023.

• Estimated total Medicare overpayment exposure (FY2020 through FY2022): Assuming referral volumes were comparable across years (which should be verified through actual claims data), the total potential Medicare overpayment exposure could range from approximately $2.5 million to $3.0 million over the life of the arrangement, and this figure continues to grow as the arrangement remains in effect.

These estimates are preliminary and subject to refinement through detailed claims-level analysis. A comprehensive overpayment calculation, including methodology for allocating referral volume between federal program and commercial payer claims, is provided in the companion CMS SRDP Evaluation Memorandum.

The magnitude of potential overpayment exposure underscores the urgency of remediation. If a Stark Law violation is identified, the 60-day repayment clock begins to run, and AHT must either return the overpayment through the standard process or make a voluntary self-disclosure through the CMS Self-Referral Disclosure Protocol.

V. ANALYSIS — ISSUE 2: CME SPONSORSHIP

A. Characterization of the Arrangement

Pinnacle sponsored four CME events for AHT physicians in FY2022, with a total sponsorship value of $86,000. The sponsorship covered the full cost of the events, including speaker fees, venue rental, catering, and CME credit administration. The events were attended by AHT physicians who practice at clinics subject to the PLA and who are sources of referrals to Pinnacle for clinical laboratory services.

The CME sponsorship constitutes a transfer of value from Pinnacle (the referral recipient) to AHT and its physicians (the referral sources). The events provided tangible benefits to AHT physicians: educational content at no cost, meals, and CME credits necessary to maintain licensure. The events were organized in connection with the preferred laboratory relationship and focused on clinical laboratory topics relevant to Pinnacle's service offerings.

The CME sponsorship is analytically distinct from the LabLink Interface issue but shares the same fundamental concern: a laboratory that receives referrals from AHT physicians is providing items of value to those physicians (and to AHT) without charge, in the context of a referral relationship that generates $1.65 million in annual laboratory revenue for Pinnacle.

B. Anti-Kickback Statute Analysis

1. Remuneration. The CME sponsorship constitutes remuneration under the AKS. By funding the entirety of the CME events, Pinnacle provides something of value — educational programming, meals, and CME credits — to AHT physicians who are in a position to refer, and who do in fact refer, laboratory services to Pinnacle. The value of the remuneration is substantial: $86,000 in aggregate across four events in a single fiscal year.

2. One-Purpose Test

Even if the primary purpose of the CME events is educational — and there is no reason to doubt that the events provided genuine educational content to attending physicians — the AKS requires only that one purpose of the remuneration be to induce or reward referrals. The factual circumstances surrounding the CME sponsorship support an inference that at least one purpose of the sponsorship is to maintain and strengthen the referral relationship between AHT physicians and Pinnacle:

• The CME events were sponsored by a laboratory that receives $1.65 million in annual referrals from the attending physicians.

• The events were organized specifically for AHT physicians, not for the general physician community. This targeted approach suggests that the events were designed, at least in part, to cultivate the referral relationship.

• The events were held at AHT clinic locations (in some cases), further integrating the sponsorship into the existing referral relationship.

• The content of the events focused on clinical laboratory topics, including advances in molecular diagnostics and appropriate laboratory utilization — topics that are directly relevant to Pinnacle's service offerings and that may influence physicians' ordering behavior in ways that benefit Pinnacle.

• The sponsorship was not managed through an independent, accredited CME provider, raising questions about the independence of the educational content from Pinnacle's commercial interests.

3. OIG Guidance

The OIG has repeatedly expressed concern about industry-sponsored CME, particularly when the sponsor has a financial interest in the referral decisions of the attending physicians. In its Special Fraud Alert on Speaker Programs (November 2020), the OIG highlighted the risk that industry-sponsored educational events may serve as vehicles for remuneration that induces referrals, even when the events have ostensible educational content. While the Special Fraud Alert focused primarily on pharmaceutical manufacturer speaker programs, the principles apply equally to laboratory-sponsored CME events.

The OIG Compliance Program Guidance for Clinical Laboratories (63 Fed. Reg. 45076, August 24, 1998) specifically addressed the provision of items and services by laboratories to referral sources. The guidance emphasized that laboratories should not provide anything of value to physicians or other referral sources as an inducement for referrals, and that items such as educational programs, gifts, and entertainment should be carefully evaluated for AKS compliance.

4. Safe Harbor Analysis

No specific CME safe harbor exists under the AKS. The personal services and management contracts safe harbor (42 C.F.R. § 1001.952(d)) does not apply because the CME sponsorship is not structured as a personal services contract. Pinnacle is not providing services under a written agreement with specified services, a term of at least one year, and aggregate compensation set in advance at FMV. Rather, Pinnacle is funding educational events for physicians who refer to it — an arrangement that does not fit within the personal services framework.

The EHR safe harbor is inapplicable to CME sponsorship. No other safe harbor protects the direct sponsorship of educational events for referral sources.

5. Risk Factors

Several factors elevate the AKS risk associated with the CME sponsorship:

(a) Direct sponsorship by a referral recipient. Pinnacle directly funds events attended by physicians who refer to it, creating a clear nexus between the remuneration and the referral relationship.

(b) Events held at AHT locations. The use of AHT clinic locations as event venues reinforces the perception that the CME events are an extension of the referral relationship rather than independent educational programming.

(c) Absence of independent accreditation. The events do not appear to have been organized or accredited by an independent ACCME-accredited CME provider. Pinnacle had input into speaker selection and topic emphasis, compromising the independence of the educational content.

(d) Substantial aggregate value. The $86,000 annual sponsorship value is not de minimis. It represents a meaningful financial benefit to AHT and its physicians.

(e) Targeted audience. The events were restricted to AHT physicians who are sources of referrals to Pinnacle, rather than open to the broader physician community. This targeting suggests that the events were designed to cultivate the specific referral relationship.

6. Overall AKS Concl

MEMORANDUM
PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
TO: Patricia Yamamoto, General Counsel, Arbor Health Technologies Inc. Derek Huang, Chief Compliance Officer, Arbor Health Technologies Inc.
FROM: Miriam Calloway, Partner, Calderwood & Harkness LLP Christopher Aiken, Senior Associate, Calderwood & Harkness LLP Amy Whitfield, Associate, Calderwood & Harkness LLP
DATE: May 15, 2023
RE: Pinnacle Laboratory Services Inc. — Detailed Analysis Under the Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) and the Physician Self-Referral Law (42 U.S.C. § 1395nn)
C&H Matter No.: 1010-00003
This memorandum is a privileged and confidential attorney-client communication and attorney work product prepared by Calderwood & Harkness LLP at the direction of Arbor Health Technologies Inc. for the purpose of providing legal advice in connection with AHT's healthcare regulatory compliance self-assessment. This memorandum is not intended for distribution to any third party without the prior written consent of Calderwood & Harkness LLP and Arbor Health Technologies Inc. Disclosure to any third party may waive applicable privileges.
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
This memorandum presents a standalone legal analysis of three discrete compliance issues arising from the relationship between Arbor Health Technologies Inc. ("AHT") and Pinnacle Laboratory Services Inc. ("Pinnacle") under the Federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b (the "AKS"), and the Federal Physician Self-Referral Law, 42 U.S.C. § 1395nn (the "Stark Law"). This memorandum has been prepared at the direction of AHT's General Counsel, Patricia Yamamoto, and Chief Compliance Officer, Derek Huang, in connection with the broader healthcare regulatory compliance self-assessment engagement between AHT and Calderwood & Harkness LLP (engagement letter dated January 30, 2023; engagement window January 30, 2023 through July 12, 2023).
This memorandum supplements, and should be read in conjunction with, the comprehensive Stark Law Compliance Assessment Memorandum and the Anti-Kickback Statute Compliance Assessment Memorandum separately prepared by Calderwood & Harkness LLP as part of the broader self-assessment engagement. Those memoranda address the full universe of AHT's physician referral arrangements and financial relationships on a portfolio-wide basis. The present memorandum narrows its focus to the Pinnacle relationship specifically, which warrants dedicated attention given its complexity and risk profile.
The Pinnacle relationship was initially identified as a "high-risk" arrangement in the gap assessment report prepared by Grayson Whitaker & Associates LLP (Report No. GW-AHT-2022-Final, dated December 12, 2022), which was commissioned by AHT prior to the engagement of Calderwood & Harkness LLP. The Grayson Whitaker report flagged several features of the arrangement that warranted further legal analysis, including the absence of fair market value ("FMV") substantiation for certain items and services, the intermingling of referral and vendor relationships, and potential undisclosed conflicts of interest. Calderwood & Harkness LLP has independently investigated the factual circumstances and conducted the legal analysis that follows.
Three issues are analyzed in this memorandum:
1. No-Cost Electronic Laboratory Interface ("LabLink Interface"). Pinnacle provides a proprietary electronic laboratory ordering and results interface integrated into AHT's ArborConnect electronic health record ("EHR") platform at zero cost to AHT, under the preferred laboratory agreement dated June 15, 2020. The estimated fair market value of this interface is approximately $120,000 per year, based on comparable SaaS licensing arrangements for laboratory interface products, as assessed by AHT internal IT and validated by preliminary benchmarking conducted by Calderwood & Harkness LLP. The interface effectively channels AHT physician laboratory orders exclusively to Pinnacle.
2. Continuing Medical Education ("CME") Sponsorship. Pinnacle sponsored four CME events for AHT physicians in fiscal year 2022, with an aggregate sponsorship value of $86,000. The events covered clinical laboratory topics and were attended by AHT physicians who are sources of referrals to Pinnacle for clinical laboratory services.
3. Dr. Karen Ellsworth's Equity Interest. Dr. Karen Ellsworth, an independent physician and the spouse of Dr. Nathan Ellsworth (Chief Executive Officer of AHT), holds a 4.2% passive equity interest in Pinnacle Laboratory Services Inc. This equity interest was not disclosed in AHT's conflict-of-interest records prior to the Grayson Whitaker gap assessment.
Referral Volume. AHT clinics located in Rhode Island and southeastern Massachusetts generated approximately $1.65 million in outpatient clinical laboratory referrals to Pinnacle in fiscal year 2022. Given AHT's overall payer mix (approximately 61% Medicare/Medicaid, 39% commercial), the estimated Medicare and Medicaid share of this referral volume is approximately $1.0 million.
Overall Risk Assessment: HIGH. Based on the analysis set forth in this memorandum, Calderwood & Harkness LLP concludes that the Pinnacle arrangement presents material compliance risk under both the AKS and the Stark Law. Each of the three issues independently raises significant legal concerns, and the three issues taken together create a compounding effect that substantially elevates the overall risk profile. Remediation is strongly recommended.
Key Recommendations. Calderwood & Harkness LLP recommends the following remedial actions, each of which is described in greater detail in Section VIII of this memorandum:
(a) Restructure the LabLink Interface to a fair market value software license arrangement, supported by an independent FMV appraisal, with terms that satisfy applicable AKS safe harbors and Stark Law exceptions;
(b) Decouple CME sponsorship from the referral relationship by transitioning to AHT-funded or independently accredited CME programming, with any residual non-monetary benefits compliant with applicable thresholds;
(c) Implement formal conflict-of-interest disclosure and management protocols for Dr. Karen Ellsworth's 4.2% equity interest in Pinnacle, including CEO recusal from Pinnacle-related decisions, board-level disclosure, and consideration of divestiture; and
(d) Evaluate whether voluntary self-disclosure is warranted under the CMS Self-Referral Disclosure Protocol ("SRDP") and the OIG Self-Disclosure Protocol ("SDP"), as discussed in the companion CMS SRDP Evaluation Memorandum and OIG SDP Evaluation Memorandum.
II. FACTUAL BACKGROUND
The following factual background is based on Calderwood & Harkness LLP's review of documents provided by AHT, interviews with AHT management and compliance personnel, the Grayson Whitaker gap assessment report, publicly available information, and other materials gathered during the course of this engagement. All factual statements herein are based on information available as of the date of this memorandum.
A. Arbor Health Technologies Inc. — Overview
Arbor Health Technologies Inc. ("AHT") is a Delaware corporation headquartered at 200 Concord Avenue, Suite 400, Cambridge, Massachusetts 02138. AHT was incorporated in Delaware in 2017 and is registered to do business in Massachusetts, Connecticut, Rhode Island, and New Hampshire.
AHT operates 23 outpatient medical clinics branded as "Arbor Health Clinics" across four states in the northeastern United States. The clinic distribution is as follows: fourteen (14) clinics in Massachusetts, four (4) clinics in Connecticut, three (3) clinics in Rhode Island, and two (2) clinics in New Hampshire. The clinics provide a range of healthcare services, including primary care, specialty care (cardiology, orthopedics, and gastroenterology), and ancillary services such as in-office laboratory testing, diagnostic imaging, and physical therapy.
In addition to its clinical operations, AHT has developed and markets a proprietary electronic health record and practice management software-as-a-service ("SaaS") platform known as "ArborConnect." ArborConnect is used internally by all 23 AHT clinics and is also licensed to 42 external physician practices, generating approximately $8.9 million in annual subscription revenue. The ArborConnect platform is central to the LabLink Interface issue discussed in this memorandum, as the Pinnacle electronic laboratory interface is integrated directly into the ArborConnect system.
For fiscal year 2022 ("FY2022"), AHT reported net revenue of $214.3 million. Of this total, Medicare and Medicaid reimbursements accounted for approximately 61%, or $130.7 million. Commercial payer revenue accounted for the remaining 39%, or approximately $83.6 million. AHT's payer mix is relevant to the magnitude of potential Stark Law exposure, as the Stark Law's prohibition on referrals and billing applies specifically to items and services payable by the Medicare program.
AHT employs 147 physicians on a W-2 basis across its 23 clinics. In addition, AHT maintains 38 independent contractor or medical director arrangements with non-employed physicians. These physicians, whether employed or under contract, are the individuals who order and refer clinical laboratory services that are at issue in the Pinnacle relationship.
AHT is a portfolio company of Ridgeline Capital Partners Fund IV, L.P. ("Ridgeline"), a private equity fund. Ridgeline acquired a 72% equity stake in AHT in January 2021 for approximately $185 million. Ridgeline's board designees are Claudia Sorrento and Marcus Whitmore, each of whom serves on AHT's Board of Directors. Ridgeline is currently anticipated to pursue an exit or sale of its AHT interest in late 2024, a fact that has significant implications for the urgency of compliance remediation, as discussed further in Section VII.C of this memorandum.
AHT's current senior leadership includes Dr. Nathan Ellsworth, Chief Executive Officer; Patricia Yamamoto, General Counsel; and Derek Huang, Chief Compliance Officer. AHT's employer identification number ("EIN") is 84-3291057. Its organizational National Provider Identifier ("NPI") is 1497253810, and its lead Provider Transaction Access Number ("PTAN") is 27MA4891.
As of the date of this memorandum, AHT has no prior federal or state healthcare enforcement actions, has not entered into a Corporate Integrity Agreement with the OIG, and has no pending OIG Advisory Opinion requests.
B. Pinnacle Laboratory Services Inc. — Overview
Pinnacle Laboratory Services Inc. ("Pinnacle") is a Rhode Island corporation with its principal place of business at 1200 Warwick Avenue, Suite 110, Warwick, Rhode Island 02886. Pinnacle's employer identification number is 05-6138290.
Pinnacle provides clinical laboratory testing services, including routine chemistry panels, hematology, complete blood counts, urinalysis, microbiology and culture testing, anatomic and clinical pathology, and specialized molecular diagnostics. Pinnacle holds appropriate CLIA certifications and state laboratory licenses for the jurisdictions in which it operates.
Pinnacle services AHT's three Rhode Island clinics and a relevant subset of AHT's fourteen Massachusetts clinics located in southeastern Massachusetts. The specific Massachusetts clinics serviced by Pinnacle include those in Fall River, New Bedford, Taunton, and Brockton. Pinnacle is the designated "preferred" outpatient clinical laboratory for these AHT clinics under the terms of the Preferred Laboratory Agreement discussed below.
Based on information gathered during this engagement, Pinnacle is a privately held company. It is not publicly traded, and its equity is not available through a registered stock exchange or over-the-counter market. This fact is relevant to the applicability of certain AKS safe harbors and Stark Law exceptions, as discussed in Sections V and VI of this memorandum.
C. The Preferred Laboratory Agreement
AHT and Pinnacle entered into a Preferred Laboratory Agreement (the "PLA") on June 15, 2020. Under the PLA, Pinnacle is designated as the "preferred" outpatient clinical laboratory for AHT's Rhode Island and southeastern Massachusetts clinics. The PLA contemplates that AHT physicians at the designated clinics will direct, or at a minimum be encouraged to direct, outpatient laboratory work to Pinnacle as the preferred provider.
In FY2022, AHT clinics subject to the PLA generated approximately $1.65 million in outpatient laboratory referrals to Pinnacle. This volume represents a material revenue stream for Pinnacle and a significant referral relationship for purposes of AKS and Stark Law analysis.
The PLA contains several provisions that are relevant to this analysis. First, the PLA provides for the designation of Pinnacle as the provider of an electronic laboratory ordering and results interface (the "LabLink Interface") integrated into AHT's ArborConnect EHR platform at no cost to AHT. Second, the PLA contemplates Pinnacle's sponsorship of continuing medical education events for AHT physicians. These two provisions form the basis of Issues 1 and 2 addressed in this memorandum.
The PLA does not contain a specific provision regarding Dr. Karen Ellsworth's equity interest in Pinnacle, nor does it include any conflict-of-interest disclosure requirements related to the financial interests of AHT officers or their immediate family members.
The PLA was executed for an initial term of three years and contains an automatic renewal provision for successive one-year terms unless either party provides written notice of non-renewal at least 90 days prior to the end of the then-current term. As of the date of this memorandum, the PLA remains in effect and has not been modified or amended since its original execution.
D. The Electronic Laboratory Interface (LabLink Interface)
Under the PLA, Pinnacle provides a proprietary electronic laboratory ordering and results interface, branded as the "LabLink Interface," which is integrated into AHT's ArborConnect EHR platform. The LabLink Interface enables AHT physicians to place clinical laboratory orders electronically from within the ArborConnect system, receive laboratory results directly in the patient's electronic health record, and generate automated billing and coding data associated with the ordered tests.
The LabLink Interface was implemented approximately in mid-2020, shortly after the execution of the PLA. It has been in continuous operation since that time. The cost to AHT for the LabLink Interface is zero dollars — the interface is provided by Pinnacle at no charge as part of the preferred laboratory arrangement.
The estimated fair market value of the LabLink Interface is approximately $120,000 per year. This estimate is based on comparable SaaS licensing arrangements for laboratory interface products, as initially assessed by AHT's internal IT department and validated by preliminary benchmarking conducted by Calderwood & Harkness LLP in consultation with industry databases and publicly available pricing information for laboratory information system interface products. A formal, independent FMV appraisal has not been conducted; Calderwood & Harkness LLP recommends engagement of Northbridge Valuation Advisors LLC for this purpose, as discussed in Section VIII.A.
A critical feature of the LabLink Interface is its exclusive routing functionality. Laboratory orders placed through ArborConnect are routed exclusively to Pinnacle. The interface does not provide AHT physicians with the option to direct laboratory orders to an alternative laboratory provider through the same workflow. This "lock-in" effect means that the LabLink Interface is not merely a convenience tool but a structural mechanism that channels referral volume to Pinnacle. To order from a different laboratory, an AHT physician would need to step outside the ArborConnect workflow and use an alternative ordering process, creating friction that discourages deviation from the Pinnacle referral pathway.
The combination of zero cost and exclusive routing makes the LabLink Interface a significant element of the Pinnacle relationship for purposes of AKS and Stark Law analysis.
E. CME Sponsorship
Pinnacle has sponsored continuing medical education events for AHT physicians under the general framework of the PLA and the broader preferred laboratory relationship. In FY2022, Pinnacle sponsored four (4) CME events for AHT physicians, with an aggregate sponsorship value of $86,000.
The sponsorship covered speaker fees, venue rental, catering and meals, and CME credit administration costs. The events were held at a combination of AHT clinic locations and external venues (hotels and conference centers). The content of the CME events focused on clinical laboratory topics, including advances in molecular diagnostics, appropriate laboratory utilization guidelines, quality improvement in laboratory testing, and emerging biomarkers in cardiology and oncology screening.
The CME events were open to AHT physicians who practice at the clinics subject to the PLA and who are sources of referrals to Pinnacle. Attendance records provided by AHT indicate that each event was attended by approximately 25 to 35 AHT physicians. The events were not open to the general physician community; they were organized specifically for AHT physicians in connection with the Pinnacle preferred laboratory relationship.
There is no evidence that the CME events were independently accredited by an ACCME-accredited CME provider. The events appear to have been organized jointly by Pinnacle and AHT's medical education department, with Pinnacle having input into speaker selection and topic emphasis. This organizational structure raises concerns about the independence of the educational content and the extent to which the CME events served a marketing or relationship-building function in addition to (or instead of) a genuine educational purpose.
F. Dr. Karen Ellsworth's Equity Interest in Pinnacle
Dr. Karen Ellsworth holds a 4.2% passive equity interest in Pinnacle Laboratory Services Inc. Dr. Karen Ellsworth is a licensed physician practicing independently in Rhode Island. She is not employed by AHT, does not hold a medical directorship or independent contractor arrangement with AHT, and does not practice at any AHT clinic.
Dr. Karen Ellsworth is the spouse of Dr. Nathan Ellsworth, who serves as Chief Executive Officer of AHT. Dr. Nathan Ellsworth is a licensed physician who assumed the CEO role at AHT in connection with the Ridgeline Capital acquisition in January 2021. As CEO, Dr. Nathan Ellsworth has ultimate management authority over AHT's clinical operations, including physician employment and supervision, vendor relationships, preferred provider designations, and referral policies. Dr. Nathan Ellsworth's authority encompasses the decision to enter into, maintain, and renew the PLA with Pinnacle.
There is no evidence in the record that Dr. Karen Ellsworth directly participates in AHT's decision-making regarding the Pinnacle relationship. She has no formal role at AHT and has not communicated with AHT personnel regarding the PLA or any aspect of the Pinnacle arrangement, based on the information available to Calderwood & Harkness LLP. However, the spousal relationship between Dr. Karen Ellsworth and Dr. Nathan Ellsworth creates a financial interest that runs through AHT's CEO. As Dr. Karen Ellsworth's equity interest in Pinnacle generates financial returns (dividends, distributions, or appreciation in equity value), the economic benefit inures to the marital household of the individual who controls AHT's referral policies and vendor relationships.
Critically, the equity interest was not disclosed in AHT's conflict-of-interest records prior to the Grayson Whitaker gap assessment in late 2022. AHT's conflict-of-interest policy requires annual disclosure by officers and directors of financial interests in entities with which AHT does business, but the policy does not explicitly require disclosure of immediate family members' financial interests. The Grayson Whitaker gap assessment identified this deficiency and recommended expansion of the disclosure requirements. Calderwood & Harkness LLP concurs with this recommendation.
III. APPLICABLE LEGAL FRAMEWORK
A. Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b))
The Federal Anti-Kickback Statute, codified at 42 U.S.C. § 1320a-7b(b), prohibits any person from knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in exchange for, or to induce, the referral of an individual for the furnishing or arranging for the furnishing of any item or service payable under a federal healthcare program, or in exchange for, or to induce, the purchasing, leasing, ordering, or arranging for or recommending purchasing, leasing, or ordering any good, facility, service, or item payable under a federal healthcare program. 42 U.S.C. § 1320a-7b(b)(1)-(2).
Clinical laboratory services are items and services covered under the Medicare and Medicaid programs and thus fall within the scope of the AKS. The referral of laboratory testing from AHT physicians to Pinnacle, to the extent such testing is payable by Medicare, Medicaid, or any other federal healthcare program, implicates the statute's prohibitions.
The AKS is interpreted broadly. The statute's use of the terms "directly or indirectly" and "in cash or in kind" Signals that the prohibition extends beyond simple cash payments and encompasses any transfer of value that may serve as an inducement to refer. The United States Court of Appeals for the Third Circuit, in United States v. Greber, 760 F.2d 68 (3d Cir. 1985), held that a violation of the AKS exists if even one purpose of a payment is to induce future referrals, regardless of whether the payment also compensates for legitimate services. This "one-purpose test" has been widely adopted by other circuits and represents the prevailing standard for AKS enforcement.
Violations of the AKS carry significant penalties. A criminal conviction under the AKS is a felony offense, punishable by up to five years of imprisonment and a fine of up to $100,000 per violation. 42 U.S.C. § 1320a-7b(b). In addition to criminal penalties, the Civil Monetary Penalties Law ("CMPL"), 42 U.S.C. § 1320a-7a, authorizes civil monetary penalties of up to $100,000 per violation, plus treble the amount of remuneration involved. Persons convicted of AKS violations are also subject to mandatory exclusion from federal healthcare programs under 42 U.S.C. § 1320a-7(a).
Furthermore, AKS violations serve as a predicate for liability under the False Claims Act ("FCA"), 31 U.S.C. § 3729 et seq. Section 1320a-7b(g) provides that a claim for items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. FCA liability exposes the violating party to treble damages and per-claim penalties (currently $13,946 to $27,894 per claim, as adjusted for inflation), as well as potential qui tam actions brought by whistleblower relators.
B. AKS Safe Harbors (42 C.F.R. § 1001.952) — Potentially Applicable
Congress directed the OIG to promulgate regulations specifying payment practices that shall not be treated as criminal offenses under the AKS. These "safe harbors," codified at 42 C.F.R. § 1001.952, define specific arrangements that, if all conditions are met, will not be subject to prosecution under the AKS. Compliance with a safe harbor is voluntary but provides definitive protection when all elements are satisfied. Failure to meet every element of a safe harbor does not necessarily mean that an arrangement violates the AKS; it means only that the arrangement does not have the benefit of safe harbor protection and must be evaluated on a case-by-case basis under the totality of the circumstances.
The following safe harbors are potentially relevant to the three issues analyzed in this memorandum:
Investment Interests Safe Harbor (42 C.F.R. § 1001.952(a)). This safe harbor protects certain returns on investment interests in entities from which the investor receives referrals or to which the investor makes referrals. For entities whose equity securities are not traded on a public exchange (as is the case with Pinnacle), the safe harbor imposes stricter requirements, commonly referred to as the "60/40 test." Specifically, for non-publicly traded entities, the safe harbor requires, among other conditions: (i) no more than 40% of the value of the investment interests may be held in the aggregate by investors who are in a position to make or influence referrals to, furnish items or services to, or otherwise generate business for the entity; (ii) no more than 40% of the entity's gross revenue related to the furnishing of healthcare items and services in the previous fiscal year or twelve-month period may come from referrals, items, or services furnished to investors; (iii) the terms on which an investment interest is offered to a passive investor who is in a position to make or influence referrals must be no different from the terms offered to other passive investors; (iv) the terms on which the investment interest is offered must not require the investor to make referrals to the entity; (v) the entity must not loan funds to or guarantee a loan for an investor who is in a position to make referrals if the loan or guarantee is used to obtain the investment interest; and (vi) the return on the investment must be directly proportional to the amount of the capital investment. 42 C.F.R. § 1001.952(a)(2).
Personal Services and Management Contracts Safe Harbor (42 C.F.R. § 1001.952(d)). This safe harbor protects payments made by a principal to an agent for services performed under a personal services or management contract, provided that several conditions are satisfied: (i) the agreement is in writing and signed by the parties; (ii) the agreement covers all services to be provided by the agent; (iii) if the agreement is for part-time or periodic services, the agreement specifies the schedule, length, and exact charge for such intervals; (iv) the term of the agreement is for not less than one year; (v) the aggregate compensation paid over the term of the agreement is set in advance, is consistent with fair market value in arm's-length transactions, and is not determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties; and (vi) the services performed do not involve the counseling or promotion of a business arrangement or other activity that violates any state or federal law. 42 C.F.R. § 1001.952(d).
Electronic Health Records Items and Services Safe Harbor (42 C.F.R. § 1001.952(y)). This safe harbor, originally promulgated in 2006 and subject to periodic sunset and reinstatement, protects certain donations of electronic health records software, information technology, and training services. As amended and extended by the 2020 Final Rule (85 Fed. Reg. 77684), the safe harbor requires, among other conditions: (i) the items and services are provided to an individual or entity engaged in the delivery of healthcare; (ii) the donor does not take any action to limit or restrict the use, compatibility, or interoperability of the donated items or services with other electronic prescribing or electronic health records systems; (iii) neither the eligibility of a recipient for the items or services, nor the amount or nature of the items or services, is determined in a manner that directly takes into account the volume or value of referrals or other business generated between the parties; (iv) the arrangement is set forth in a written agreement signed by the parties; and (v) the donor does not have actual knowledge of, and does not act in reckless disregard or deliberate ignorance of, the fact that the recipient possesses or has obtained items or services equivalent to those provided. 42 C.F.R. § 1001.952(y).
C. Physician Self-Referral Law (Stark Law) (42 U.S.C. § 1395nn)
The Physician Self-Referral Law, commonly known as the "Stark Law," is codified at 42 U.S.C. § 1395nn and its implementing regulations at 42 C.F.R. Part 411, Subparts J and K. The Stark Law operates as a strict liability prohibition: it does not require proof of intent, knowledge, or willfulness. If the elements of the prohibition are met and no exception applies, a violation exists regardless of the parties' state of mind.
The Stark Law provides that if a physician (or an immediate family member of such physician) has a "financial relationship" with an entity, the physician may not make a referral to the entity for the furnishing of "designated health services" ("DHS") payable by the Medicare program, unless an exception applies. 42 U.S.C. § 1395nn(a)(1). Furthermore, the entity may not present or cause to be presented a claim to Medicare (or bill any other individual, entity, or third-party payer) for DHS furnished pursuant to a prohibited referral. 42 U.S.C. § 1395nn(a)(1)(B).
Designated Health Services. The Stark Law identifies ten categories of DHS, including clinical laboratory services. 42 U.S.C. § 1395nn(h)(6). Pinnacle provides clinical laboratory testing services that fall squarely within this category.
Financial Relationship. The term "financial relationship" encompasses two types of arrangements: (1) an ownership or investment interest in the entity, including equity interests, debt instruments, or other means of investment; and (2) a compensation arrangement between the physician (or an immediate family member) and the entity. 42 U.S.C. § 1395nn(a)(2); 42 C.F.R. § 411.354. Both direct and indirect financial relationships are covered.
Immediate Family Member. The Stark Law extends the prohibition to referrals by a physician whose "immediate family member" has a financial relationship with the DHS entity. The term "immediate family member" is defined at 42 C.F.R. § 411.351 to include, among others, a spouse.
Referral. The term "referral" is defined broadly to include "the request by a physician for, or ordering of, or the certifying or recertifying of the need for" any designated health service. 42 U.S.C. § 1395nn(h)(5).
Penalties. Violations of the Stark Law result in: (i) denial of payment for the DHS furnished pursuant to the prohibited referral; (ii) an obligation to refund any amounts collected for such DHS; (iii) civil monetary penalties of up to $15,000 per service furnished pursuant to a prohibited referral; (iv) for circumvention schemes, a civil monetary penalty assessment of up to $100,000; and (v) potential exclusion from federal healthcare programs. 42 U.S.C. § 1395nn(g); 42 C.F.R. § 411.353.
D. Stark Law Exceptions — Potentially Applicable
The Stark Law provides numerous exceptions, codified at 42 U.S.C. § 1395nn(b)-(e) and 42 C.F.R. §§ 411.355-411.357. If an exception applies, the prohibition on referrals and billing does not attach. The following exceptions are potentially relevant to the issues analyzed in this memorandum:
Ownership/Investment Interest Exception for Publicly Traded Securities and Mutual Funds (42 C.F.R. § 411.356(a)). This exception applies to ownership of investment securities that may be purchased on terms generally available to the public and that are listed on a registered national securities exchange or traded under an automated interdealer quotation system. Because Pinnacle does not appear to be a publicly traded entity, this exception is not applicable to Dr. Karen Ellsworth's equity interest.
Ownership/Investment Interest in Rural Providers (42 C.F.R. § 411.356(c)). This exception permits ownership or investment interests in entities that furnish DHS in a "rural area," as defined in the regulations. Pinnacle is located in Warwick, Rhode Island, which is a suburb of Providence and is not classified as a rural area under applicable definitions (including the Census Bureau's designation of the Providence-Warwick-Pawtucket metropolitan statistical area). This exception is not applicable.
Indirect Compensation Arrangement Exception (42 C.F.R. § 411.357(p)). This exception applies to indirect compensation arrangements and requires that: (i) the compensation received by the referring physician (or immediate family member) under the arrangement does not vary with, and is not otherwise determined by taking into account, the volume or value of referrals or other business generated by the referring physician; (ii) the compensation arrangement is set out in writing, is signed by the parties, and specifies the services covered by the arrangement; and (iii) the compensation provided under the arrangement is consistent with FMV for services or items actually provided and is not determined in a manner that takes into account the volume or value of referrals or other business generated between the parties.
Non-Monetary Compensation Exception (42 C.F.R. § 411.357(k)). This exception permits an entity that furnishes DHS to provide non-monetary compensation to a referring physician if the aggregate value of the non-monetary compensation does not exceed the annual threshold established by CMS. For calendar year 2023, this threshold is $459 per physician. The exception does not apply if the physician has specifically requested the compensation.
Fair Market Value Exception (42 C.F.R. § 411.357(l)). This exception applies to compensation arrangements for the provision of items or services (other than the rental of office space or equipment) that meet the following requirements: (i) the arrangement is in writing, signed by the parties, and specifies the items or services covered; (ii) the arrangement covers only identifiable items or services; (iii) the compensation is set in advance, does not exceed FMV, and is not determined in a manner that takes into account the volume or value of referrals; and (iv) the arrangement is commercially reasonable.
Value-Based Enterprise Exceptions (42 C.F.R. § 411.357(aa)). The CMS Final Rule effective January 19, 2021 (85 Fed. Reg. 77492) established new Stark Law exceptions for value-based arrangements. These exceptions permit certain remuneration exchanged between participants in a "value-based enterprise" that is reasonably designed to achieve at least one value-based purpose. The applicability of these exceptions depends on whether AHT and Pinnacle could constitute a "value-based enterprise" and whether any arrangement between them qualifies as a "value-based arrangement" as defined in the regulations. Based on preliminary analysis, the AHT-Pinnacle relationship does not appear to be structured as a value-based enterprise, and no value-based arrangement appears to exist between the parties. However, a more detailed analysis of this exception is reserved for the comprehensive Stark Law Compliance Assessment Memorandum.
E. State Law Overlay
In addition to the federal AKS and Stark Law, several state laws may be implicated by the Pinnacle arrangement. Of particular relevance is the Massachusetts Anti-Kickback Law, codified at M.G.L. c. 175H, § 3, which prohibits the payment or receipt of remuneration for the referral of patients in connection with healthcare services. Unlike the federal AKS, which applies only to items and services payable by federal healthcare programs, the Massachusetts Anti-Kickback Law extends to referrals involving commercial payer patients. This broader scope means that the 39% of AHT's revenue attributable to commercial payers — approximately $83.6 million in FY2022 — may be subject to state-level kickback prohibitions in Massachusetts.
AHT's southeastern Massachusetts clinics that refer laboratory work to Pinnacle involve both federal program patients and commercial payer patients. Accordingly, even if the federal AKS analysis were limited to the Medicare/Medicaid share of referral volume, the Massachusetts Anti-Kickback Law may capture the full scope of referral-related remuneration.
A detailed analysis of Massachusetts state law applicability is provided in the companion Massachusetts Anti-Kickback Law (M.G.L. c. 175H, § 3) Applicability Memorandum. Rhode Island healthcare anti-fraud statutes (R.I. Gen. Laws § 27-60-1 et seq.) and their potential applicability to the Pinnacle arrangement should also be evaluated and are addressed in the comprehensive AKS Compliance Assessment Memorandum.
IV. ANALYSIS — ISSUE 1: NO-COST ELECTRONIC LABORATORY INTERFACE
A. Characterization of the Arrangement
The threshold question for both AKS and Stark Law analysis is whether the provision of the LabLink Interface at zero cost constitutes "remuneration." Under both statutes, remuneration is defined broadly to include transfers of anything of value, directly or indirectly, overtly or covertly, in cash or in kind. The LabLink Interface is a functional, commercially available software product with an estimated fair market value of approximately $120,000 per year. Its provision at no cost to AHT constitutes a transfer of value — i.e., remuneration — from Pinnacle to AHT.
The remuneration flows from Pinnacle (an entity that receives referrals from AHT physicians for clinical laboratory services that are DHS under the Stark Law and items payable by federal healthcare programs under the AKS) to AHT (the entity whose physicians make the referrals that generate Pinnacle's revenue). This directionality of the remuneration — from the recipient of referrals to the source of referrals — is precisely the type of arrangement that both statutes are designed to address.
The LabLink Interface is directly tied to the PLA and facilitates referrals by making it operationally easier, faster, and more seamless for AHT physicians to order laboratory services from Pinnacle. The interface eliminates the need for AHT physicians to complete paper requisitions, call Pinnacle directly, or use an alternative ordering system. The integration of the LabLink Interface into ArborConnect means that ordering from Pinnacle is the default workflow; ordering from any other laboratory requires additional effort and deviation from the standard process.
Most significantly, the LabLink Interface creates a structural "lock-in" effect. Because orders placed through ArborConnect route exclusively to Pinnacle, the interface channels referral volume to Pinnacle with no competing option within the same workflow. This lock-in effect strengthens the inference that the interface serves as an inducement to refer to Pinnacle. The interface is not merely a neutral technology tool; it is a referral-generating mechanism embedded in the physician's daily clinical workflow, provided at no cost by the entity that benefits from the referrals it generates.
B. Anti-Kickback Statute Analysis
1. Prima Facie Case
The elements of a potential AKS violation are present. Pinnacle provides an item of value — the LabLink Interface, with an estimated FMV of $120,000 per year — to AHT, an entity whose physicians refer clinical laboratory services to Pinnacle. In FY2022, AHT physicians referred approximately $1.65 million in outpatient laboratory services to Pinnacle. Under the "one-purpose test" articulated in United States v. Greber, a reasonable inference exists that at least one purpose of the no-cost interface is to induce or reward referrals from AHT physicians to Pinnacle for laboratory services payable by federal healthcare programs.
The inference of inducement is supported by several factual indicators. First, the LabLink Interface was provided contemporaneously with the PLA, which designated Pinnacle as the preferred laboratory for AHT's relevant clinics. The interface and the preferred laboratory designation are components of a single integrated arrangement. Second, the interface creates a lock-in effect that channels referrals exclusively to Pinnacle. Third, the value of the interface ($120,000 per year) is substantial — it is not a de minimis courtesy or incidental convenience. Fourth, there is no independent commercial rationale for Pinnacle to provide a $120,000-per-year product at no cost other than the generation and retention of referral volume.
2. Safe Harbor Analysis — Personal Services (42 C.F.R. § 1001.952(d))
The personal services and management contracts safe harbor does not apply to the LabLink Interface arrangement. The provision of the interface is not structured as a personal services contract. The PLA does not contain a separate, written agreement specifying the LabLink Interface as a service with aggregate compensation set in advance at fair market value. Rather, the interface is bundled into the broader preferred laboratory arrangement as a zero-cost component. There is no specification of the services to be performed, no identification of the schedule of services, and no aggregate compensation that is set in advance and consistent with FMV. Accordingly, the personal services safe harbor does not protect this arrangement.
3. Safe Harbor Analysis — Electronic Health Records (42 C.F.R. § 1001.952(y))
The EHR items and services safe harbor requires careful analysis. This safe harbor was designed to encourage the adoption and use of electronic health records technology by permitting certain donations of EHR software and related services. However, the safe harbor was not designed to protect laboratory-specific ordering interfaces that function as referral-channeling mechanisms tied to a preferred provider relationship.
Calderwood & Harkness LLP has analyzed each element of the EHR safe harbor against the LabLink Interface arrangement:
(a) Written Agreement. The safe harbor requires that the arrangement be set forth in a written agreement signed by the parties that covers all of the items and services to be provided. The PLA references the LabLink Interface but does not contain the level of specificity required by the safe harbor — it does not separately identify the software components, functionality, support services, or other items and services constituting the "donation," nor does it include the specific representations and certifications contemplated by the safe harbor regulations.
(b) Interoperability. The safe harbor requires that the donor not take any action to limit or restrict the use, compatibility, or interoperability of the donated items or services with other electronic prescribing or EHR systems. The LabLink Interface, by design, routes laboratory orders exclusively to Pinnacle. It does not interoperate with other laboratory service providers. AHT physicians cannot use the LabLink Interface to order from a competing laboratory. This exclusive routing functionality represents a significant restriction on interoperability and is inconsistent with the safe harbor's requirement that the donated technology not be artificially limited to channel business to the donor.
(c) Volume or Value of Referrals. The safe harbor requires that neither the eligibility of the recipient for the items or services nor the amount or nature of the items or services be determined in a manner that directly takes into account the volume or value of referrals or other business generated between the parties. The LabLink Interface is provided exclusively in connection with the PLA, which designates Pinnacle as the preferred laboratory. The interface is, by its nature, linked to the referral relationship — it exists to facilitate referrals to Pinnacle. While the interface is provided at a flat zero-cost rate (not nominally tied to referral volume), its provision is inseparable from the preferred laboratory designation and the referral volume that designation generates. This coupling raises serious concerns about whether the arrangement satisfies the safe harbor's prohibition on volume-or-value-based determinations.
(d) Purpose of the Safe Harbor. More broadly, the EHR safe harbor was intended to promote the adoption of interoperable EHR technology, not to protect proprietary laboratory ordering interfaces that function as competitive lock-in mechanisms. The LabLink Interface is a narrow, single-purpose tool designed to route orders to Pinnacle. It is not an EHR system or a component of an EHR system in the traditional sense; it is a laboratory-specific ordering module that serves Pinnacle's commercial interests. Extending the EHR safe harbor to protect this type of arrangement would be inconsistent with the safe harbor's underlying policy rationale.
Conclusion: The EHR safe harbor likely does not protect the LabLink Interface arrangement in its current form. The exclusive routing functionality, the absence of interoperability with competing laboratories, the coupling of the interface with the preferred laboratory referral designation, and the lack of a sufficiently specific written agreement all present significant obstacles to safe harbor compliance.
4. Other Safe Harbors
No other AKS safe harbor appears applicable to the no-cost provision of the LabLink Interface. The arrangement does not qualify as a discount, a warranty, or a bona fide employment relationship. The waiver-of-coinsurance safe harbor is not relevant. The group purchasing organization safe harbor does not apply. The arrangement does not fall within the scope of the managed care safe harbor or the referral services safe harbor.
5. Overall AKS Conclusion on Issue 1
The no-cost provision of the LabLink Interface presents a significant AKS violation risk. The arrangement involves the transfer of substantial value ($120,000 per year) from a laboratory that receives referrals to the entity whose physicians make those referrals, in connection with a preferred laboratory designation that generates $1.65 million in annual referral volume. No safe harbor protects the arrangement in its current form. Under the one-purpose test, the likelihood that a government enforcement authority would conclude that at least one purpose of the no-cost interface is to induce referrals is substantial.
C. Stark Law Analysis
1. Compensation Arrangement Analysis
Under the Stark Law, the no-cost provision of the LabLink Interface constitutes remuneration from Pinnacle to AHT, creating a compensation arrangement between a DHS entity (Pinnacle, which provides clinical laboratory services) and an entity whose physicians make referrals for DHS. The existence of this compensation arrangement triggers the Stark Law prohibition unless an applicable exception is met.
2. Non-Monetary Compensation Exception (42 C.F.R. § 411.357(k))
The non-monetary compensation exception permits an entity that furnishes DHS to provide non-monetary compensation to a referring physician, provided that the aggregate value of the non-monetary compensation does not exceed the annual threshold established by CMS. For calendar year 2023, the threshold is $459 per physician per calendar year.
The LabLink Interface has an estimated fair market value of $120,000 per year. Even if this value is allocated across all AHT physicians who use the interface for laboratory ordering, the per-physician value substantially exceeds the $459 threshold. For example:
• If 50 AHT physicians regularly use the LabLink Interface, the per-physician allocation is $120,000 ÷ 50 = $2,400 per physician per year — more than five times the annual limit.
• If 100 AHT physicians use the interface (an unlikely scenario given that only a subset of AHT's 147 employed physicians practice at the clinics subject to the PLA), the per-physician allocation is $120,000 ÷ 100 = $1,200 per physician per year — still more than 2.6 times the annual limit.
• Even under the most generous allocation assumptions, the per-physician value of the LabLink Interface far exceeds $459.
Accordingly, the non-monetary compensation exception does not protect this arrangement.
3. Fair Market Value Exception (42 C.F.R. § 411.357(l))
The fair market value exception requires that compensation under the arrangement be consistent with fair market value for identifiable items or services actually provided. The LabLink Interface is provided at zero cost — not at FMV. Because the compensation (zero) is not consistent with the FMV of the services provided (approximately $120,000 per year), the fair market value exception does not apply. This exception could only be satisfied if AHT paid Pinnacle FMV for the interface, which is precisely the remedial action recommended in Section VIII.A.
4. Indirect Compensation Arrangement Exception (42 C.F.R. § 411.357(p))
If the LabLink Interface is characterized as compensation flowing from Pinnacle to AHT (rather than directly to individual physicians), the referring physicians' relationship with Pinnacle may be analyzed as an indirect compensation arrangement under 42 C.F.R. § 411.354(c). Under this analysis, there is an unbroken chain of financial relationships between Pinnacle (which provides remuneration in the form of the LabLink Interface to AHT) and the AHT physicians (who are employed by or under contract with AHT and who make referrals to Pinnacle for DHS).
The indirect compensation arrangement exception at 42 C.F.R. § 411.357(p) requires, among other things, that the compensation received by the physician (or immediate family member) under the arrangement does not vary with, and is not otherwise determined by taking into account, the volume or value of referrals or other business generated by the referring physician for the entity furnishing DHS.
This requirement is difficult to satisfy in the context of the LabLink Interface. Although the interface itself is provided at a flat rate (zero), it is provided in connection with the PLA, which designates Pinnacle as the preferred laboratory. The preferred laboratory designation is inherently tied to referral volume — it exists to generate referrals to Pinnacle. The LabLink Interface, as a component of the preferred laboratory arrangement, is linked to the $1.65 million in annual referral volume that the PLA generates. Whether the "compensation" (the no-cost interface) technically "varies with" the volume or value of referrals is debatable, but the functional nexus between the interface and the referral volume creates a substantial argument that the exception's requirements are not met.
Moreover, the exception requires that the compensation be consistent with FMV and not take into account the volume or value of referrals. As discussed above, the zero-cost provision of a $120,000-per-year product is not consistent with FMV.
5. Overall Stark Law Conclusion on Issue 1
The no-cost provision of the LabLink Interface likely constitutes a non-excepted compensation arrangement that renders referrals from AHT physicians to Pinnacle for DHS non-compliant under the Stark Law. No exception available under current regulations appears to protect the arrangement in its present form. If this analysis is correct, every referral from an AHT physician to Pinnacle for clinical laboratory services payable by Medicare that has occurred during the period the LabLink Interface has been in place (approximately June 2020 to the present) is a prohibited referral, and every Medicare claim submitted by Pinnacle for such services is a prohibited claim.
D. Overpayment and Refund Exposure
If the Stark Law is violated, all claims for DHS (clinical laboratory services) referred by AHT physicians to Pinnacle and billed to Medicare are subject to the statutory prohibition on billing and the refund obligation. Under 42 U.S.C. § 1395nn(g)(2), any person who collects any amounts that were billed in violation of the Stark Law is obligated to refund such amounts. Furthermore, under 42 U.S.C. § 1320a-7k(d), an overpayment must be reported and returned to the applicable payer within 60 days of the date on which the overpayment was identified, or the date any corresponding cost report is due, whichever is later. Failure to timely return an identified overpayment may give rise to FCA liability.
The potential overpayment exposure is calculated as follows:
• FY2022 referral volume to Pinnacle: Approximately $1.65 million total.
• Medicare/Medicaid share: Approximately 61% (consistent with AHT's overall payer mix) = approximately $1.0 million in Medicare/Medicaid-payable referrals.
• Duration of the arrangement: The LabLink Interface has been in place since approximately June 2020, encompassing FY2020 (partial year, approximately six months), FY2021 (full year), and FY2022 (full year), with the arrangement continuing into FY2023.
• Estimated total Medicare overpayment exposure (FY2020 through FY2022): Assuming referral volumes were comparable across years (which should be verified through actual claims data), the total potential Medicare overpayment exposure could range from approximately $2.5 million to $3.0 million over the life of the arrangement, and this figure continues to grow as the arrangement remains in effect.
These estimates are preliminary and subject to refinement through detailed claims-level analysis. A comprehensive overpayment calculation, including methodology for allocating referral volume between federal program and commercial payer claims, is provided in the companion CMS SRDP Evaluation Memorandum.
The magnitude of potential overpayment exposure underscores the urgency of remediation. If a Stark Law violation is identified, the 60-day repayment clock begins to run, and AHT must either return the overpayment through the standard process or make a voluntary self-disclosure through the CMS Self-Referral Disclosure Protocol.
V. ANALYSIS — ISSUE 2: CME SPONSORSHIP
A. Characterization of the Arrangement
Pinnacle sponsored four CME events for AHT physicians in FY2022, with a total sponsorship value of $86,000. The sponsorship covered the full cost of the events, including speaker fees, venue rental, catering, and CME credit administration. The events were attended by AHT physicians who practice at clinics subject to the PLA and who are sources of referrals to Pinnacle for clinical laboratory services.
The CME sponsorship constitutes a transfer of value from Pinnacle (the referral recipient) to AHT and its physicians (the referral sources). The events provided tangible benefits to AHT physicians: educational content at no cost, meals, and CME credits necessary to maintain licensure. The events were organized in connection with the preferred laboratory relationship and focused on clinical laboratory topics relevant to Pinnacle's service offerings.
The CME sponsorship is analytically distinct from the LabLink Interface issue but shares the same fundamental concern: a laboratory that receives referrals from AHT physicians is providing items of value to those physicians (and to AHT) without charge, in the context of a referral relationship that generates $1.65 million in annual laboratory revenue for Pinnacle.
B. Anti-Kickback Statute Analysis
1. Remuneration. The CME sponsorship constitutes remuneration under the AKS. By funding the entirety of the CME events, Pinnacle provides something of value — educational programming, meals, and CME credits — to AHT physicians who are in a position to refer, and who do in fact refer, laboratory services to Pinnacle. The value of the remuneration is substantial: $86,000 in aggregate across four events in a single fiscal year.
2. One-Purpose Test
Even if the primary purpose of the CME events is educational — and there is no reason to doubt that the events provided genuine educational content to attending physicians — the AKS requires only that one purpose of the remuneration be to induce or reward referrals. The factual circumstances surrounding the CME sponsorship support an inference that at least one purpose of the sponsorship is to maintain and strengthen the referral relationship between AHT physicians and Pinnacle:
• The CME events were sponsored by a laboratory that receives $1.65 million in annual referrals from the attending physicians.
• The events were organized specifically for AHT physicians, not for the general physician community. This targeted approach suggests that the events were designed, at least in part, to cultivate the referral relationship.
• The events were held at AHT clinic locations (in some cases), further integrating the sponsorship into the existing referral relationship.
• The content of the events focused on clinical laboratory topics, including advances in molecular diagnostics and appropriate laboratory utilization — topics that are directly relevant to Pinnacle's service offerings and that may influence physicians' ordering behavior in ways that benefit Pinnacle.
• The sponsorship was not managed through an independent, accredited CME provider, raising questions about the independence of the educational content from Pinnacle's commercial interests.
3. OIG Guidance
The OIG has repeatedly expressed concern about industry-sponsored CME, particularly when the sponsor has a financial interest in the referral decisions of the attending physicians. In its Special Fraud Alert on Speaker Programs (November 2020), the OIG highlighted the risk that industry-sponsored educational events may serve as vehicles for remuneration that induces referrals, even when the events have ostensible educational content. While the Special Fraud Alert focused primarily on pharmaceutical manufacturer speaker programs, the principles apply equally to laboratory-sponsored CME events.
The OIG Compliance Program Guidance for Clinical Laboratories (63 Fed. Reg. 45076, August 24, 1998) specifically addressed the provision of items and services by laboratories to referral sources. The guidance emphasized that laboratories should not provide anything of value to physicians or other referral sources as an inducement for referrals, and that items such as educational programs, gifts, and entertainment should be carefully evaluated for AKS compliance.
4. Safe Harbor Analysis
No specific CME safe harbor exists under the AKS. The personal services and management contracts safe harbor (42 C.F.R. § 1001.952(d)) does not apply because the CME sponsorship is not structured as a personal services contract. Pinnacle is not providing services under a written agreement with specified services, a term of at least one year, and aggregate compensation set in advance at FMV. Rather, Pinnacle is funding educational events for physicians who refer to it — an arrangement that does not fit within the personal services framework.
The EHR safe harbor is inapplicable to CME sponsorship. No other safe harbor protects the direct sponsorship of educational events for referral sources.
5. Risk Factors
Several factors elevate the AKS risk associated with the CME sponsorship:
(a) Direct sponsorship by a referral recipient. Pinnacle directly funds events attended by physicians who refer to it, creating a clear nexus between the remuneration and the referral relationship.
(b) Events held at AHT locations. The use of AHT clinic locations as event venues reinforces the perception that the CME events are an extension of the referral relationship rather than independent educational programming.
(c) Absence of independent accreditation. The events do not appear to have been organized or accredited by an independent ACCME-accredited CME provider. Pinnacle had input into speaker selection and topic emphasis, compromising the independence of the educational content.
(d) Substantial aggregate value. The $86,000 annual sponsorship value is not de minimis. It represents a meaningful financial benefit to AHT and its physicians.
(e) Targeted audience. The events were restricted to AHT physicians who are sources of referrals to Pinnacle, rather than open to the broader physician community. This targeting suggests that the events were designed to cultivate the specific referral relationship.
6. Overall AKS Concl

MEMORANDUM

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

I. EXECUTIVE SUMMARY

II. FACTUAL BACKGROUND

III. APPLICABLE LEGAL FRAMEWORK

Record

Parties

Dates

Amounts